



PCT

## (51) International Patent Classification:

C07D 261/14 (2006.01) A61P 13/12 (2006.01)  
C07D 261/06 (2006.01) A61K 31/553 (2006.01)  
A61P 11/06 (2006.01)

## (21) International Application Number:

PCT/US2009/068106

## (22) International Filing Date:

15 December 2009 (15.12.2009)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/122,568 15 December 2008 (15.12.2008) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street, Suite 100, San Diego, California 92121 (US).

## (72) Inventor; and

(71) Applicant : **WANG, Bowei** [US/US]; 10 Kirkview Circle, Westfield, New Jersey 07090 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **HUTCHINSON, John, Howard** [US/US]; 5948 Via Zurita, La Jolla, California 92037 (US). **SEIDERS, Thomas, Jon** [US/US]; 5257 Soledad Mountain Road, San Diego, California 92109 (US). **ARRUDA, Jeannie, M.** [US/US]; 3611 Florida St. #4, San Diego, California 92104 (US). **ROPPE, Jeffrey, Roger.** [US/US]; 32182 Camino Guard, Temecula, California 92592 (US). **PARR, Timothy** [US/US]; 8504 Lemon Avenue, La Mesa, California 91941 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

[Continued on next page]

## (54) Title: ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS




FIGURE 1

(57) Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.



ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

- (88) **Date of publication of the international search report:**

26 August 2010

**Declarations under Rule 4.17:**